All articles by Phillip Broadwith
-
-
OpinionTrump steps up pharma tariff threat
Taxing branded drug imports could hit biotech innovators hardest
-
OpinionA global petrochemical shift
China’s rapid capacity expansion fuels global oversupply, leading plant closures in Europe and elsewhere
-
BusinessFatal incidents at chemical plants in the US, India and Norway
Hydrogen and acid explosions, a fluorochemicals plant gas leak and a heavy lifting incident claimed at least four lives
-
OpinionIs UK pharma really ‘uninvestable’?
Merck & Co, AstraZeneca (AZ) and Eli Lilly pulling UK projects highlights the precarious position of the country’s life sciences industry
-
BusinessTwo workers killed in fire at fertiliser plant in Gujarat, India
A second fire the same day in Gujarat was tackled without casualties
-
OpinionUK biofuels burning out
With UK plants facing closure, what are the options and issues around different renewable fuels?
-
OpinionDeadly fentanyl contamination exposes drug safety challenges
Bacterial contamination in medical fentanyl has killed at least 51 people in Argentina, highlighting pressures on generic drugmakers
-
BusinessWill oral weight loss drugs challenge injectables?
Pills may offer convenience for manufacturers, but it’s not clear they will overtake existing drugs
-
OpinionCheap virgin plastic limits recycling potential
Global plastic treaty negotiations risk being derailed by minority opposed to production caps
-
BusinessMerck & Co to cut 6000 jobs, Moderna to cut around 500
Both firms aiming to make significant reductions in annual costs by reorganising
-
OpinionIntergovernmental panel on chemicals, waste and pollution needs diverse input
Balancing industrial expertise against unwanted commercial influence is not easy but shouldn’t be discounted
-
OpinionLosing sleep over pesticide exposure
Managing exposure risks poses questions about the extent of producers’ and regulators’ responsibilities for safety
-
OpinionChina’s drug development charge
Reforms and state support have fuelled domestic and foreign investment in pharmaceutical
-
-
BusinessWill HIV prevention get where it’s needed?
Gilead and its partners’ efforts to distribute generic lenacapavir could be derailed by cuts in international aid budgets
-
Business11 executives jailed over Italian PFAS pollution
Convictions relate to groundwater contamination around Miteni fluorochemicals plant
-
OpinionCritical metals supply strained
Conflict - both military and political - is having profound effects on supplies of a wide range of materials
-
OpinionThe future of oil refining in the UK
Can plants adapt to be compatible with a lower-carbon environment?
-
BusinessSanofi to buy Blueprint Medicines for over $9 billion
Blueprint has one approved drug and enhances Sanofi’s immunology portfolio